The Impact of Antibody-Drug Conjugates in Bladder Cancer and Gynecologic Malignancies

This activity is part 1 in a 4-part webinar series. 

Program Description

Antibody-drug conjugates (ADCs) have provided another therapeutic option for patients with bladder cancer or gynecologic malignancies who have progressed on first-line therapy. Oncology pharmacists are central to the success of treatment regimens utilizing ADCs in both of these populations. This webinar will cover revised guideline recommendations for the emerging role of ADCs in advanced and metastatic bladder, cervical, and ovarian cancers. As some ADCs are currently under investigation, this webinar will outline the role of oncology pharmacists in preparing for the integration of these therapies into current clinical pathways and treatment protocols.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: May 11, 2023
Expiration date: July 11, 2023

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Distinguish among therapeutic targets for antibody-drug conjugates (ADCs) in bladder, ovarian, and cervical cancers
• Differentiate clinical data and treatment considerations for use of ADCs across bladder cancer and gynecologic malignancies
• Explain the rationale for treatment selection and sequencing of ADCs in the treatment of bladder, ovarian, and cervical cancers
• Investigate the gaps in systemic treatment strategies and potential place in therapy of investigational ADCs in gynecologic malignancies

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-133-L01-P. The activity is available for CE credit through July 11, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Emma J. Jones, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA; Amy L. Morris, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms